Ninlaro

Drug - Ninlaro® (ixazomib) [Millennium Pharmaceuticals, Inc.]

May 2016

Therapeutic area - Oncology

Approval criteria

• Patient must be 18 years of age or older AND
• Have a diagnosis of multiple myeloma AND
• Must be prescribed in combination with lenalidomide and dexamethasone AND
• Patient has had at least one prior treatment for multiple myeloma AND
• Patient has not had prior therapy with lenalidomide or proteasome inhibitors AND
• If female, patient is not pregnant or planning to become pregnant and should be advised to avoid pregnancy for 90 days following the final dose of Ninlaro

Quantity limit

Maximum of 3 capsules per 28 days

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411